These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25875396)

  • 1. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.
    Calza L; Colangeli V; Magistrelli E; Bussini L; Conti M; Ramazzotti E; Mancini R; Viale P
    HIV Med; 2017 Aug; 18(7):474-481. PubMed ID: 28116848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
    Calza L; Mosca L; Pocaterra D; Piergentili B; Colangeli V; Manfredi R; Erario A; Grossi G; Verucchi G; Viale P
    Eur J Clin Pharmacol; 2011 Feb; 67(2):143-9. PubMed ID: 20878151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.
    Curran A; Martí R; López RM; Pérez M; Crespo M; Melià MJ; Navarro J; Burgos J; Falcó V; Ocaña I; Ribera E
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6782-90. PubMed ID: 26282411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
    Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
    Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers.
    Soon GH; Shen P; Yong EL; Pham P; Flexner C; Lee L
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2775-80. PubMed ID: 20385850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
    Rockstroh J; Teppler H; Zhao J; Sklar P; Harvey C; Strohmaier K; Leavitt R; Nguyen BY
    HIV Med; 2012 Feb; 13(2):127-31. PubMed ID: 21599819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
    Jackson A; Watson V; Back D; Khoo S; Liptrott N; Egan D; Gedela K; Higgs C; Abbas R; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2011 Dec; 58(5):450-7. PubMed ID: 21926632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
    Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
    HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
    Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Breidinger SA; Mangin EC; Azrolan N; Greenberg HE; Haazen W; Stone JA; Gottesdiener KM; Wagner JA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A validated method for simultaneous quantification of four antiretrovirals in dried blood spot and plasma using LC-MS/MS: Application to efavirenz therapeutic drug monitoring in pregnant patients.
    Ludna Duarte M; Mikaelle Brandão Silva A; Wellithom Viturino da Silva J; Pereira Santana D; Victor de Castro W; Cláudio Arraes de Alencar L; César Galindo Bedor D; Bastos Leal L
    Clin Biochem; 2024 May; 127-128():110765. PubMed ID: 38649089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
    Quercia R; Roberts J; Martin-Carpenter L; Zala C
    Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
    Jackson A; Moyle G; Dickinson L; Back D; Khoo S; Taylor J; Gedela K; Abongomera G; Gazzard B; Boffito M
    Antivir Ther; 2012; 17(1):19-24. PubMed ID: 22267465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
    Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
    J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
    Moltó J; Llibre JM; Ribera E; Mínguez C; del Río JS; Pedrol E; Vallecillo G; Cedeño S; Valle M; Miranda C; Negredo E; Clotet B;
    J Antimicrob Chemother; 2009 May; 63(5):992-7. PubMed ID: 19279052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.
    Di Yacovo MS; Moltó J; Ferrer E; Curran A; Else L; Gisslén M; Clotet B; Tiraboschi JM; Niubò J; Vila A; Zetterberg H; Back D; Podzamczer D
    J Antimicrob Chemother; 2015 May; 70(5):1513-6. PubMed ID: 25608583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.